Ovarian Cancer Pipeline Drugs Report 2025: Innovative Drug Developments and Ongoing Clinical Studies Uncovered

DelveInsight's "Ovarian Cancer Pipeline Insight 2025" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Ovarian Cancer pipeline landscape. It covers the Ovarian Cancer Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ovarian Cancer Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Ovarian Cancer Pipeline? Click here to explore the therapies and trials making headlines @ Ovarian Cancer Pipeline Outlook Report- https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Ovarian Cancer Pipeline Report
• 03 October 2025, AGO Research GmbH announced a study is allow to evaluate the safety and feasibility in a stepwise approach. A trial steering committee (TSC) meeting will take place between the cohorts to review safety and feasibility prior to starting the second cohort. The safety follow-up of the first cohort will take 90 days as of the first dose of therapy.
• O3 October 2025, Daiichi Sankyo conducted a clinical trial is designed to evaluate the efficacy and safety of T-DXd in combination with bevacizumab versus bevacizumab monotherapy as first-line maintenance therapy, in participants with human epidermal growth factor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+/2+/1+) advanced high-grade epithelial ovarian cancer.
• DelveInsight's Ovarian Cancer Pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Ovarian Cancer treatment.
• The leading Ovarian Cancer Companies such as Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
• Promising Ovarian Cancer Therapies such as SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab,and others.

Want to know which companies are leading innovation in Ovarian Cancer? Dive into the full pipeline insights @ Ovarian Cancer Clinical Trials Assessment- https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Ovarian Cancer Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Ovarian Cancer Pipeline Report also highlights the unmet needs with respect to the Ovarian Cancer.

Ovarian Cancer Overview
Ovarian cancer is the leading cause of death in women diagnosed with gynecological cancers. It is also the fifth most frequent cause of death in women, in general. Most of the cases are diagnosed at an advanced stage, which leads to poor outcomes of this disease. The existing screening tests have a low predictive value contributing further to this misery. Detailed gynecological evaluation along with transvaginal ultrasound and laboratory marker like cancer antigen-125 (CA-125) assay are the key early detection strategies which have shown no significant beneficial effect in the morbidity or mortality of this cancer.

Ovarian Cancer Emerging Drugs
• Atezolizumab: Genentech
Atezolizumab is a humanized kappa immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy chains (448 amino acids) and two light chains (214 amino acids) and is produced in Chinese hamster cells. Atezolizumab was engineered to eliminate Fc-effector function via a single amino acid substitution (asparagine to alanine) at position 298 on the heavy chain, which results in a non-glycosylated antibody that has minimal binding to Fc receptors and, consequently, eliminates detectable Fc-effector function and depletion of cells expressing programmed death-ligand 1 (PD-L1) in humans. Atezolizumab targets human PD-L1 and inhibits its interaction with its receptors, programmed death-1 (PD-1) and B7.1, both of which can provide inhibitory signals to T cells. The drug is currently in phase 3 of clinical trials for the treatment of Ovarian Cancer.

• Tisotumab Vedotin: Genmab
Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis. Tisotumab vedotin includes an antibody targeting TF conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. The drug is currently in phase 2 of clinical trials for the treatment of Ovarian Cancer.

• SON-1010: Sonnet Biotherapeutics
SON-1010 is a proprietary version of native human IL-12, configured using Sonnet's fully human albumin binding (FHAB®) platform, which targets the tumor microenvironment (TME) and extends the pharmacokinetics (PK) and subsequent pharmacodynamics (PD) of the molecule. Sonnet and Roche have entered into a Master Clinical Trial and Supply Agreement (MCSA), along with ancillary Quality and Safety Agreements, to study the safety and efficacy of the combination of SON-1010 and atezolizumab in a platinum-resistant ovarian cancer (PROC) patient setting. Currently the drug is in the Phase I/II stage of its development for the treatment of ovarian cancer.

• DS-6000a: Daiichi Sankyo Company
DS-6000a is an antibody-drug conjugate, comprised of an humanized anti-CDH6 IgG1 monoclonal antibody attached to a topoisomerase I (TOP1) inhibitor payload via a cleavable linker. DS-6000a specifically binds to CDH6 on the surface of tumor cells and is internalized upon binding. The payload is then released, resulting in target cell apoptosis. In preclinical studies, DS-6000a inhibited tumor growth and induced tumor regression in CDH6-expressing RCC and OVC. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Ovarian Cancer.

If you're tracking ongoing Ovarian Cancer Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Ovarian Cancer Treatment Drugs- https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

The Ovarian Cancer Pipeline report provides insights into:-
• The report provides detailed insights about companies that are developing therapies for the treatment of Ovarian Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer Treatment.
• Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.

Ovarian Cancer Companies
Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Covis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.

Ovarian Cancer Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as,
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Ovarian Cancer Products have been categorized under various Molecule types such as,
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Ovarian Cancer Pipeline Report covers it all - check it out now @ Ovarian Cancer Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Ovarian Cancer Pipeline Report
• Coverage- Global
• Ovarian Cancer Companies- Allarity Therapeutics, OSE Immunotherapeutic, Cristal Therapeutics, Bristol-Myers Squibb, Ono Pharmaceuticals, Merck & Co., Aravive Biologics, Mersana Therapeutics, Clovis Oncology, Verastem Oncology, Gradalis, AbbVie, Elevation Oncology, OncoQuest Pharmaceuticals (CanariaBio), Alkermes, Hoffman-la Roche, AstraZeneca, MSD, GlaxoSmithKline, IMV, Corcept Therapeutics and others.
• Ovarian Cancer Therapies- SAR245409, Karenitecin, Topotecan, OTL38, Magrolimab, Avelumab,and others.
• Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research - discover what's next for the Ovarian Cancer Treatment landscape in this detailed analysis @ Ovarian Cancer Emerging Drugs and Major Players- https://www.delveinsight.com/sample-request/ovarian-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Ovarian Cancer: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ovarian Cancer- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Tisotumab Vedotin: Genmab
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. DS-6000a: Daiichi Sankyo Company
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Product Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Ovarian Cancer Key Companies
21. Ovarian Cancer Key Products
22. Ovarian Cancer- Unmet Needs
23. Ovarian Cancer- Market Drivers and Barriers
24. Ovarian Cancer- Future Perspectives and Conclusion
25. Ovarian Cancer Analyst Views
26. Ovarian Cancer Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.